Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2

Conditions

Thyroid Neoplasms 5Thyroid Cancer, Papillary 2Carcinoma, Non-Small-Cell Lung 2Thyroid Diseases 1Thyroid Carcinoma, Anaplastic 1Sexual Dysfunction, Physiological 1Neoplasms 1Gastrointestinal Neoplasms 1Eunuchism 1Erectile Dysfunction 1Carcinoma, Medullary 1Cachexia-Anorexia Syndrome 1Breast Neoplasms 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1Adenocarcinoma, Follicular 1

Interventions

Iodine-131 5dabrafenib 4Vemurafenib 4Magnetic Resonance Spectroscopy 4trametinib 3lenvatinib 3Transurethral Resection of Prostate 3Thyrotropin Alfa 3Thyroidectomy 3selpercatinib 2cobimetinib 2X-Rays 2Thyroid (USP) 2Surgical Procedures, Operative 2Sunitinib 2Specimen Handling 2Radiofrequency Ablation 2Interviews as Topic 2vandetanib 1tremelimumab 1spartalizumab 1pembrolizumab 1pazopanib 1durvalumab 1delta 24-sterol reductase 1copanlisib 1cabozantinib 1Whole Body Imaging 1Thyrotropin 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Thyroid Cancer, Papillary × selpercatinib × Clear all
NCT04759911 2026-05-20

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT05668962 2024-12-12

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Massachusetts General Hospital

Phase 2 Recruiting
30 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡